| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel; and
Department of Surgery "A," Assaf Harofeh Medical Center, Tel-Aviv University, Zerifin, Israel
CTL and NK cells use two distinct cytocidal pathways: 1) perforin and granzyme based and 2) CD95L/CD95 mediated. The former requires perforin expression by the effectors (CTL or NK), whereas the latter requires CD95 (Fas/APO-1) expression by the target. We have investigated how these two factors contribute to tumor immune surveillance by studying the immunity of perforin-deficient mice against the progressor C57BL/6 Lewis lung carcinoma 3LL, which expresses no CD95 when cultured in vitro. Unexpectedly, the results indicated that the perforin-independent CD95L/CD95 pathway of CTL/NK plays a role in acting against D122 and Kb39.5 (39.5) high and low metastatic sublines, respectively, derived from the 3LL tumor. Although no membrane-bound CD95 was detected on cultured D122 and 39.5 cells, surface CD95 expression on both D122 and 39.5 was considerably up-regulated when the tumors were grown in vivo. A similarly enhanced expression of CD95 was observed with three additional tumors; LF-, BW, and P815, injected into syngeneic and allogeneic mice. The finding of up-regulated CD95 expression on tumor cells placed in vivo suggests that a CD95-based mechanism plays a role in tumor immunity at early stages of tumor growth. Consequently, the progressive down-regulation of CD95 expression during tumor progression may indeed be an escape mechanism as previously reported. Together, these results suggest a role for CD95-dependent, perforin-independent immunity against certain tumors.
This article has been cited by other articles:
|
|
 |
|
  Z. Su, J. Kuball, A.-P. Barreiros, D. Gottfried, E. A. Ferreira, M. Theobald, P. R. Galle, D. Strand, and S. Strand Nitric Oxide Promotes Resistance to Tumor Suppression by CTLs J. Immunol., April 1, 2006; 176(7): 3923 - 3930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Reed and M. Pellecchia Apoptosis-based therapies for hematologic malignancies Blood, July 15, 2005; 106(2): 408 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Hollenbaugh, J. Reome, M. Dobrzanski, and R. W. Dutton The Rate of the CD8-Dependent Initial Reduction in Tumor Volume Is Not Limited by Contact-Dependent Perforin, Fas Ligand, or TNF-Mediated Cytolysis J. Immunol., August 1, 2004; 173(3): 1738 - 1743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hayakawa, V. Screpanti, H. Yagita, A. Grandien, H.-G. Ljunggren, M. J. Smyth, and B. J. Chambers NK Cell TRAIL Eliminates Immature Dendritic Cells In Vivo and Limits Dendritic Cell Vaccination Efficacy J. Immunol., January 1, 2004; 172(1): 123 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ruiz-Ruiz, G. Robledo, E. Cano, J. M. Redondo, and A. Lopez-Rivas Characterization of p53-mediated Up-regulation of CD95 Gene Expression upon Genotoxic Treatment in Human Breast Tumor Cells J. Biol. Chem., August 22, 2003; 278(34): 31667 - 31675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Woolf, C. Xiao, O. Fainaru, J. Lotem, D. Rosen, V. Negreanu, Y. Bernstein, D. Goldenberg, O. Brenner, G. Berke, et al. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis PNAS, June 24, 2003; 100(13): 7731 - 7736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Seki, A. D. Brooks, C. R. D. Carter, T. C. Back, E. M. Parsoneault, M. J. Smyth, R. H. Wiltrout, and T. J. Sayers Tumor-Specific CTL Kill Murine Renal Cancer Cells Using Both Perforin and Fas Ligand-Mediated Lysis In Vitro, But Cause Tumor Regression In Vivo in the Absence of Perforin J. Immunol., April 1, 2002; 168(7): 3484 - 3492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Screpanti, R. P. A. Wallin, H.-G. Ljunggren, and A. Grandien A Central Role for Death Receptor-Mediated Apoptosis in the Rejection of Tumors by NK Cells J. Immunol., August 15, 2001; 167(4): 2068 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Topham, R. C. Cardin, J. P. Christensen, J. W. Brooks, G. T. Belz, and P. C. Doherty Perforin and Fas in murine gammaherpesvirus-specific CD8+ T cell control and morbidity J. Gen. Virol., August 1, 2001; 82(8): 1971 - 1981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Helmich and R. W. Dutton The Role of Adoptively Transferred CD8 T Cells and Host Cells in the Control of the Growth of the EG7 Thymoma: Factors That Determine the Relative Effectiveness and Homing Properties of Tc1 and Tc2 Effectors J. Immunol., June 1, 2001; 166(11): 6500 - 6508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zheng, F. Ouaaz, P. Bruzzo, V. Singh, S. Gerondakis, and A. A. Beg NF-{{kappa}}B RelA (p65) Is Essential for TNF-{{alpha}}-Induced Fas Expression but Dispensable for Both TCR-Induced Expression and Activation-Induced Cell Death J. Immunol., April 15, 2001; 166(8): 4949 - 4957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Peng, J. C. Krauss, G. E. Plautz, S. Mukai, S. Shu, and P. A. Cohen T Cell-Mediated Tumor Rejection Displays Diverse Dependence Upon Perforin and IFN-{gamma} Mechanisms That Cannot Be Predicted From In Vitro T Cell Characteristics J. Immunol., December 15, 2000; 165(12): 7116 - 7124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Plautz, S. Mukai, P. A. Cohen, and S. Shu Cross-Presentation of Tumor Antigens to Effector T Cells Is Sufficient to Mediate Effective Immunotherapy of Established Intracranial Tumors J. Immunol., October 1, 2000; 165(7): 3656 - 3662. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
